Recruiting PHASE1 INTERVENTIONAL 4-arm NCT07381829

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of the Combination Therapy With HC010 for Injection in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose Range-Finding and Multiple Cohort Dose Expansion Phase Ib Clinical Trial-Lung Cancer Population

Sponsor: HC Biopharma Inc.

Conditions Advanced Solid Tumor Cancer

Interventions Carboplatin/Cisplatin Docetaxel Etoposide HC010 Paclitaxel (Chemotherapy) Pemetrexed

Updated 1 time since 2026 Last updated: Jan 26, 2026 Started: Oct 27, 2025 Primary completion: Dec 30, 2026 Completion: Dec 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07381829, this PHASE1 trial focuses on Advanced Solid Tumor Cancer and remains actively recruiting participants. Sponsored by HC Biopharma Inc., it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Recruiting — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HC Biopharma Inc.

Data source: HC Biopharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China